Free Trial

Greenwich LifeSciences (GLSI) Competitors

Greenwich LifeSciences logo
$10.84 -0.38 (-3.39%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$10.82 -0.02 (-0.14%)
As of 07/11/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GLSI vs. ZVRA, TYRA, TSHA, OPT, BCYC, KURA, SEPN, ABVX, MAZE, and PRME

Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), Taysha Gene Therapies (TSHA), Opthea (OPT), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Septerna (SEPN), Abivax (ABVX), Maze Therapeutics (MAZE), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry.

Greenwich LifeSciences vs. Its Competitors

Zevra Therapeutics (NASDAQ:ZVRA) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

In the previous week, Zevra Therapeutics had 10 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 11 mentions for Zevra Therapeutics and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.89 beat Zevra Therapeutics' score of 0.94 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company Overall Sentiment
Zevra Therapeutics Positive
Greenwich LifeSciences Very Positive

Zevra Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Greenwich LifeSciences has lower revenue, but higher earnings than Zevra Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zevra Therapeutics$23.61M29.02-$105.51M-$1.90-6.59
Greenwich LifeSciencesN/AN/A-$15.79M-$1.26-8.60

Greenwich LifeSciences has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -226.78%. Zevra Therapeutics' return on equity of -201.05% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Zevra Therapeutics-226.78% -201.05% -53.55%
Greenwich LifeSciences N/A -450.87%-333.18%

Zevra Therapeutics currently has a consensus price target of $23.71, suggesting a potential upside of 89.26%. Greenwich LifeSciences has a consensus price target of $39.00, suggesting a potential upside of 259.78%. Given Greenwich LifeSciences' higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than Zevra Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zevra Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Greenwich LifeSciences
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Zevra Therapeutics beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLSI vs. The Competition

MetricGreenwich LifeSciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$149.99M$2.97B$5.62B$9.10B
Dividend YieldN/A2.39%5.24%4.00%
P/E Ratio-8.6020.7128.1320.27
Price / SalesN/A288.38428.2998.73
Price / CashN/A42.8637.4658.16
Price / Book57.057.638.045.49
Net Income-$15.79M-$55.05M$3.18B$250.45M
7 Day Performance8.02%8.43%3.62%4.78%
1 Month Performance14.47%5.42%4.06%7.67%
1 Year Performance-30.65%2.03%30.01%16.43%

Greenwich LifeSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLSI
Greenwich LifeSciences
2.1731 of 5 stars
$10.84
-3.4%
$39.00
+259.8%
-31.3%$149.99MN/A-8.603Positive News
ZVRA
Zevra Therapeutics
3.1299 of 5 stars
$11.27
+15.7%
$23.14
+105.3%
+105.1%$532.58M$23.61M-5.9320News Coverage
Analyst Forecast
Analyst Revision
High Trading Volume
TYRA
Tyra Biosciences
3.1499 of 5 stars
$9.61
-3.9%
$30.83
+220.8%
-46.0%$530.90MN/A-5.9020
TSHA
Taysha Gene Therapies
4.0645 of 5 stars
$2.34
-4.5%
$8.20
+250.4%
+7.3%$525.92M$8.33M-6.88180News Coverage
Analyst Forecast
OPT
Opthea
0.273 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+72.2%$524.84M$120K0.008Gap Up
BCYC
Bicycle Therapeutics
3.7407 of 5 stars
$7.17
-3.5%
$25.00
+248.7%
-64.0%$514.56M$35.28M-2.28240News Coverage
KURA
Kura Oncology
4.4175 of 5 stars
$5.68
-3.1%
$24.50
+331.3%
-71.4%$507.33M$53.88M-2.70130
SEPN
Septerna
1.5588 of 5 stars
$10.85
-4.6%
$26.75
+146.5%
N/A$506.63M$1.08M0.00N/ANews Coverage
ABVX
Abivax
2.4644 of 5 stars
$7.95
-0.1%
$31.00
+289.9%
-38.1%$505.10MN/A0.0061Positive News
High Trading Volume
MAZE
Maze Therapeutics
N/A$12.12
+5.4%
$25.67
+111.8%
N/A$503.67M$167.50M0.00121News Coverage
Analyst Forecast
Analyst Revision
PRME
Prime Medicine
3.9254 of 5 stars
$3.80
+22.2%
$10.08
+165.4%
-27.5%$498.92M$3.85M-1.85234Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:GLSI) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners